Citations

Clear

4207 citation(s) found for "Chen, Yu".

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy
Masri, Ahmad , Cappelli, Francesco , Davis, Margot K., Fontana, Marianna , Gillmore, Julian D. , Hanna, Mazen, Solomon, Scott D. , Sperry, Brett W. , Waddington-Cruz, Márcia, Kristen, Arnt V., Falk, Rodney H. , Nativi-Nicolau, José , Viney, Nicholas J. , Yang, Qingqing , Chen, Jersey , Maurer, Mathew S. , Garcia-Pavia, Pablo , Gillmore, Julian D , Obici, Laura , Solomon, Scott David , Sperry, Brett W , Tahara, Nobuhiro , Waddington-Cruz, Márcia , Falk, Rodney H , Shah, Sanjiv J , Nativi-Nicolau, Jose , Tsimikas, Sotirios , Maurer, Mathew S , Cappelli, Francesco , Fontana, Marianna , Hanna, Mazen , Obici, Laura , Waddington‐Cruz, Márcia , Kristen, Arnt V.

Mayo Clinic

Circulation: Heart Failure | May 9, 2026 | Volume: 19 | Issue: 6 | Pages: No page available

10.1161/circheartfailure.126.014205 | PMID 42104840 Get It

BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded transthyretin (TTR) in the myocardium. Eplontersen is an N-acetylgalactosamine ligand–conjugated antisense oligonucleotide targeting hepatocyte TTR messenger RNA to reduce the production of circulating TTR. METHODS: CARDIO-TTRansform is a Phase 3, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of eplontersen in transthyretin amyloidosis with cardiomyopathy. Key inclusion criteria include histological evidence of amyloid deposits or grade 2 to 3 cardiac uptake on cardiac scintigraphy in the absence of plasma cell dyscrasia, New York Heart Association class I–III, and end-diastolic interventricular septum thickness >12 millimeters. Participants were randomized 1:1 to receive eplontersen 45 mg or placebo, administered subcutaneously every 4 weeks for up to 140 weeks, followed by a 20-week post-treatment evaluation period or open-label extension. Participants received locally available standard of care, including unrestricted use of TTR stabilizers. The primary end point is a composite of cardiovascular mortality and recurrent clinical cardiovascular events through 140 weeks. Secondary end points, in order of testing hierarchy, include changes from baseline in 6-minute walk distance and Kansas City Cardiomyopathy Questionnaire overall summary score, recurrent cardiovascular events, all-cause mortality, the primary end point in the patient subgroup receiving stabilizers at baseline, and cardiovascular mortality. Echocardiography was performed in all participants, with cardiovascular magnetic resonance imaging and technetium scintigraphy in a subset. CONCLUSIONS: CARDIO-TTRansform is fully enrolled, with 1432 randomized participants who were dosed with study drug or placebo. As the largest transthyretin amyloidosis with cardiomyopathy study to date, it will evaluate whether eplontersen improves cardiovascular outcomes in patients receiving locally available standard of care, including TTR stabilizers. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04136171. URL: http://ClinicalTrialsRegister.eu ; Unique identifier: EudraCT number 2019-002835-27.
0743 Vibrance-2: A Randomized Phase 2 Study Evaluating Efficacy and Safety of the Orexin 2 Receptor Agonist Alixorexton in Patients with Narcolepsy Type 2
BOGAN, RICHARD, Plazzi, Giuseppe, Mignot, Emmanuel, Corser, Bruce, Yee, Brendon, Garcia-Borreguero, Diego, Ruoff, Chad, Plante, David, Chen, Hailu , Lovett, Alexandra, Hopkinson, Craig, Rege, Bhaskar, Himes, Julie, Ruoff, Chad , Ruoff, Chad M , Bogan, Richard , Plazzi, Giuseppe , Villegas, Rafael del Río , Corser, Bruce, Yee, Brendon John , Garcı́a-Borreguero, Diego

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A331-A332

10.1093/sleep/zsag091.0742 Get It

Abstract Introduction Narcolepsy type 2 (NT2) is characterized by excessive daytime sleepiness, heterogeneous symptom severity, and typically normal endogenous orexin levels. The Vibrance-2 phase 2 study evaluated alixorexton, a selective orexin 2 receptor agonist, in patients with NT2. Methods Vibrance-2 was a placebo-controlled, dose-ranging phase 2 study. After a 2-week washout from current narcolepsy medications, adults with NT2 meeting ICSD-3-TR diagnostic criteria were randomized 1:1:1:1 to receive placebo or alixorexton once daily at doses of 10, 14, or 18mg for 8 weeks, followed by an optional 5-week open-label extension. Dual primary endpoints were the change from baseline to week 8 in mean sleep latency (MSL) on the Maintenance of Wakefulness Test (MWT) and on the Epworth Sleepiness Scale (ESS). Safety evaluation included treatment-emergent adverse events (TEAEs). P-values were adjusted for multiplicity. Results Ninety-three patients were randomized to placebo (n=24) or alixorexton (10mg, n=23; 14mg, n=22; 18mg, n=24); 90 completed double-blind treatment. At baseline, patients had severe symptoms (MWT: 5.6 minutes; ESS: 17.4). The study met its dual primary endpoints. At week 8, MSL on MWT increased 9.3, 6.7, and 6.7 minutes at 10, 14, and 18mg, respectively, from baseline versus placebo, with statistically significant differences observed for the 14 and 18mg doses (adjusted p< 0.05). ESS improved by -2.1, -3.2, and -3.6 points from baseline versus placebo at week 8 for the 10, 14, and 18mg groups, respectively, with statistical significance observed for the 18mg dose (adjusted p< 0.05), where more than 70% of patients achieved normalization. TEAEs in 10% of all alixorexton-treated patients through week 8 were pollakiuria, insomnia, micturition urgency, dizziness, and headache. Most TEAEs were mild-to-moderate with no serious TEAEs. Conclusion Vibrance-2 was the first large clinical trial in patients with NT2 to demonstrate positive results with an orexin 2 receptor agonist. Alixorexton resulted in statistically significant and clinically meaningful improvements in wakefulness and daytime sleepiness at Week 8 and was generally well tolerated. These results support phase 3 clinical development of alixorexton as a treatment for NT2. Support (if any) Alkermes, Inc.
0731 Cognitive and Functional Outcomes from the Phase 3 Open-Label Extension and Randomized-Withdrawal ENCORE Trial of AXS-12 in Narcolepsy with Cataplexy
Corser, Bruce, Thorpy, Michael, Krahn, Lois, BOGAN, RICHARD, Shapiro, Colin, Chen, Dan, Chhabra, Angad, Tabuteau, Herriot, Corser, Bruce, Krahn, Lois E., Bogan, Richard , Shapiro, Colin M.

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A326-A326

10.1093/sleep/zsag091.0730 Get It

Abstract Introduction AXS-12 (reboxetine) is a highly selective norepinephrine reuptake inhibitor and cortical dopamine modulator under development for the treatment of narcolepsy. Long-term efficacy and safety of AXS-12 in participants with narcolepsy with cataplexy (NT1) were previously reported from the Phase 3 ENCORE trial. To better understand the impact of AXS-12 on overall functional burden in NT1, we evaluated changes in cognition and functional outcomes during the ENCORE trial. Methods ENCORE included a 24-week open-label extension (OLE) period, followed by a 3-week double-blind randomized-withdrawal (DBRW) period. During the OLE, participants received AXS-12 (5 mg once-daily for 1 week, twice-daily for 23 weeks). Following this, participants were randomized 1:1 to continue twice-daily AXS-12 for 3 weeks or switch to once-daily AXS-12 plus placebo for 1 week, then placebo twice-daily for 2 weeks. P-values reported are nominal. Results ENCORE enrolled 68 participants; 42 completed the OLE and entered the DBRW (AXS-12, n=22; placebo, n=20). In the OLE, participants treated with AXS-12 reported improvement in the NSAQ Ability to Concentrate item at 1 (54.8%) and 6 (58.5%) months. Participants reported improvement in concentration, assessed by PGI-C, at 1 (66.7%) and 6 (70.0%) months. Narcolepsy overall, assessed by the CGI-C, improved at 1 (90.3%) and 6 (90.2%) months; and improved at 1 (77.8%) and 6 (80.0%) months, assessed by the PGI-C. Functional impairment, assessed by the WPAI, was reduced from 53.0% at baseline to 34.0% at 1 month and 24.3% at 6 months. In the DBRW, a greater proportion of participants switched to placebo experienced worsening on the NSAQ Ability to Concentrate item (52.6% vs 14.3%; P=0.011), and PGI-C for ability to concentrate (57.9% vs 22.2%; P=0.029) at 3 weeks compared with those continuing AXS-12. A greater proportion switched to placebo also reported worsening of their narcolepsy overall (PGI-C) at 3 weeks compared with those continuing AXS-12 (52.6% vs 16.7%; P=0.024). Treatment with AXS-12 was generally well tolerated. Conclusion Long-term, open-label treatment with AXS-12 was associated with improvements in cognitive/functional domains and productivity. Randomized withdrawal to placebo led to worsening cognition and narcolepsy overall. These results further support the long-term therapeutic benefit of AXS-12 for narcolepsy. Support (if any) Axsome Therapeutics Inc.
CDCP1 Deletion Protects Against Pressure Overload-Induced Cardiac Dysfunction and Fibrosis in Mice
Pereira, Naveen, Ghazal, Rachad, wang, Min, Cao, Jenny Jia Ling, Wang, Li , Sherman, William , John, August, Vyas, Hridyanshu , Roos, Carolyn, Huang, Runqing, Ördög, Tamás , Trussoni, Christy, Lim, Do Young , Sinagra, Gianfranco, Weinshilboum, Richard M. , Liu, Duan , Lambert, Laura , Miller, Jordan , Tschumperlin, Daniel, Srinivas, Akshatha N. , Sherman, Will A , Ordog, Tamas , Wang, Chen , Baker, Darren J , Weinshilboum, Richard M. , Liu, Duan , Lambert, Laura J, Pereira, Naveen, Ghazal, Rachad , Cao, Jenny Jia Ling , Wang, Li, Marín-Goñi, Irene , Wang, Chen , Trussoni, Christy E. , Baker, Darren J. , Sinagra, Gianfranco , Tschumperlin, Daniel J.

Mayo Clinic

No container title available | May 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9236741/v1 | PMID 42147194 Get It

Abstract Human genomic studies link reduced CUB domain-containing protein 1 (CDCP1) expression with myocardial recovery in heart failure. While CDCP1 regulates cardiac fibroblast proliferation in vitro, it’s in vivo role in cardiac fibrosis remains unclear. Using a Cdcp1 -knockout (KO) angiotensin II/phenylephrine mouse model, we show that Cdcp1 deletion reduces echocardiographic left ventricular mass, histologic cardiac fibrosis, and pro-fibrotic gene expression, along with decreased fibroblast activation and inflammatory markers. Spatial transcriptomics identified a pressure overload–expanded fibroblast subpopulation enriched for growth factor and TGF-β signaling (FB5), which was markedly attenuated in Cdcp1 -KO hearts, alongside reduction of a pro-inflammatory cardiomyocyte subtype (CM4). Complementary studies in human ventricular fibroblasts demonstrate that CDCP1 knockdown reduced extracellular matrix gene expression and collagen I deposition. These findings establish CDCP1 as a regulator of cardiac fibrotic remodeling in vivo and open avenues for its further investigation as a potential therapeutic target.
Web-Based Amblyopia Decision Support Tool
Summers, Allison I. , Hatch, S.W., Wiecek, Emily , Hribar, Michelle R. , Robinson, Julianne L., Chen, Angela M., Kulp, Marjean T., Chen, Debora M. Lee, Repka, Michael X., Roberts, Tawna L. , Wallace, David K. , Vricella, Marilyn, Chang, Steven, Stutz, Kathleen M., Beaulieu, Wesley T., Kraker, Raymond T., Cotter, Susan A., Holmes, Jonathan M., Weise, Katherine K., Pineles, Stacy L., (PEDIG), Pediatric Eye Disease Investigator Group, Hatt, Sarah R. , Chen, Angela M. , Kulp, Marjean Taylor , Repka, Michael X. , Wang, Jingyun, Beaulieu, Wesley T , Kraker, Raymond T. , Cotter, Susan A. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | May 7, 2026 | Volume: 144 | Issue: 6 | Pages: 545

10.1001/jamaophthalmol.2026.1095 | PMID 42096234 Get It

Importance Amblyopia is the leading cause of monocular decreased best-corrected vision in children. Early detection and intervention are key for optimal treatment outcomes; however, limited access to pediatric eye specialists may hinder timely care and affect visual outcomes. Given the shortage of specialty-trained eye care professionals in the US, there is need to support comprehensive eye care professionals who are willing to examine and treat children with amblyopia. Objective A panel from the Pediatric Eye Disease Investigator Group synthesized relevant literature and incorporated consensus opinion where direct evidence was lacking to create the Amblyopia Navigator Decision-Support Instrument, a free, web-based amblyopia decision support tool for eye care professionals. Evidence Review The decisions related to optimal diagnostic measures, pass/refer criteria, and management recommendations were informed by 147 publications. In areas where direct evidence was lacking, guidance was supplemented with clinical trial protocols or existing professional guidelines. When data were conflicting or unavailable, recommendations were established through committee consensus. A single reviewer independently performed standardized (though not systematic) literature reviews to avoid missing pertinent recent publications. Findings Presented are the process used, supporting evidence, and recommendations for testing methods, refractive correction, amblyopia treatment options, treatment adjustments, and monitoring schedules. Conclusions and Relevance Because amblyopia is common and typically responds well to treatment, decision support tools that optimize its management could increase access to pediatric eye care by facilitating earlier detection, enabling broader participation of primary eye care professionals, and ultimately improving visual outcomes. Through this work and the development of the forthcoming free, web-based application version, Amblyopia Navigator Decision-Support Instrument, the Pediatric Eye Disease Investigator Group has created decision support tools designed to assist optometrists and ophthalmologists in the care of children aged 3 to 17 years with amblyopia.
Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson's Disease
Chiu, Shannon , Wang, Wei‐en , Chen, Robin , Adler, Charles H., Mehta, Shyamal H. , Dresler, Sara R. , Armstrong, Melissa J., McFarland, Nikolaus, Okun, Michael, Vaillancourt, David E., Initiative, Parkinson's Progression Markers, Chiu, Shannon Y , Dresler, Sara R , DeSimone, Jesse C. , Archer, Derek B. , Adler, Charles H. , Armstrong, Melissa J. , McFarland, Nikolaus R. , Okun, Michael S. , Vaillancourt, David E.

Mayo Clinic

Annals of Neurology | May 7, 2026 | Volume: 100 | Issue: 2 | Pages: 295-304

10.1002/ana.78252 | PMID 42095555 Get It

Objective Positive α‐synuclein seed amplification assay (SAA) is a biomarker found in most people with Parkinson's disease (PD). We explored if free‐water (FW) imaging detects microstructural differences in the brains of patients with early PD with SAA+ or SAA– status. Methods We studied patients with PD with baseline diffusion imaging and α‐synuclein SAA data from the Parkinson's Progression Markers Initiative (PPMI). We compared FW, FW corrected fractional anisotropy (FA T ), and clinical characteristics between SAA+ and SAA– groups. We also applied the Automated Imaging Differentiation for Parkinsonism (AIDP) at baseline to classify PD versus atypical parkinsonism, stratified by SAA status. Results Among 462 participants (41 SAA– and 421 SAA+), individuals with SAA+ had hyposmia and shorter motor symptom duration before baseline magnetic resonance imaging (MRI). AIDP identified PD in 92.4% (n = 427, 91.6% had SAA+) and classified 7.6% as atypical parkinsonism (n = 35, 85.7% had SAA+). At baseline, SAA+ individuals had lower FW in the superior cerebellar peduncle, compared to SAA– (pFDR < 0.05). No significant differences in FA T were found between groups. Interpretation Positive α‐synuclein SAA was associated with focal microstructural differences but did not distinguish broader diffusion MRI (dMRI) changes across FW and FA T metrics. These findings indicate that molecular confirmation of synuclein aggregation (via SAA) provides limited stratification of neurodegeneration detected by FW imaging in early PD. ANN NEUROL 2026;100:295–304
An APOE *4-Informed Genomic Atlas of the X Chromosome in Alzheimer’s Disease
Cook, Noah , Zeng, Youjie , Yang, Chenyu , Jiang, Zhiwen , Wang, Ting‐Chen , Guen, Yann Le , Cody, Karly Alex , Johnson, Matthew, Zhang, Rui, Merritt, Victoria C. , Hauger, Richard L. , Program, the VA Million Veteran, FinnGen, Koran, Mary Ellen, Mormino, Elizabeth C. , Gordon, Brian , DeCasien, Alex, Andrews, Shea J. , Logue, Mark, Greicius, Michael D. , Le Guen, Yann , Cody, Karly A , Koran, Mary Ellen , Gordon, Brian A , Andrews, Shea , Dumitrescu, Logan , Archer, Derek , Seto, Mabel , Pottier, Cyril , Cruchaga, Carlos , Sherva, Richard , Logue, Mark W. , Napolioni, Valerio , Belloy, Michael E , Cook, Noah , Zeng, Youjie , Yang, Chenyu , Zhang, Rui, Merritt, Victoria C. , Hauger, Richard L. , Koran, Mary Ellen I. , Mormino, Elizabeth C. , DeCasien, Alex R. , Dumitrescu, Logan , Archer, Derek B. , Hohman, Timothy J. , Belloy, Michaël E.

Mayo Clinic

No container title available | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.05.26352461 | PMID 42145643 Get It

Abstract The genetic contributions of the X chromosome to Alzheimer’s disease (AD) remain poorly understood yet are expected to importantly shape sex differences in AD. We therefore performed large-scale X-chromosome-wide association studies (N=1,240,451), evaluating differential risk due to sex, APOE *4, and escape from X-chromosome inactivation, finding most X-linked loci appear relevant to female-biased AD etiology. In evaluating genetic pleiotropy with hormonal, lipid, and brain imaging traits, we discovered X-linked AD loci converged on white matter traits, particularly in the anterior corona radiata and splenium of the corpus callosum. Through brain-centric functional genomics analyses, we then nominated candidate causal genes, including 5 that appeared highly robust. Notably, we found the escape gene RBBP7 decreases AD risk in APOE *4 carriers likely through higher expression in excitatory neurons to counter tau-related neurodegeneration. Altogether, we provide an atlas of sex and APOE *4-informed candidate X-linked AD risk loci, genes, and mechanisms that will guide future studies.
Tumor mutational and microbial profiles of early-onset and later-onset colorectal cancers according to detailed tumor location: an international pooled analysis
Ugai, Tomotaka, Ugai, Satoko , Qu, Conghui, Toland, Amanda E., French, Amy J. , Gsur, Andrea , Chan, Andrew T., Guelpen, Bethany van, Lynch, Brigid, Um, Caroline Y., Newton, Christina, Thomas, Claire E., Buchanan, Daniel D., Drew, David, Goode, Ellen L., Aglago, Elom K., Brenner, Hermann, Figueiredo, Jane C., Huyghe, Jeroen R., Nowak, Jonathan A., Doheny, Kimberly F., Hsu, Li, Boardman, Lisa, Gunter, Marc J., Giannakis, Marios, Jenkins, Mark A., Obon-Santacana, Mereia, Hoffmeister, Michael, Song, Mingyang, Murphy, Neil, Campbell, Peter T., He, Qianchuan, Trinh, Quang M., Pai, Rish K. , Steinfelder, Robert S. , Berndt, Sonja I., Gruber, Stephen B., Gallinger, Steven, Zaidi, Syed H., Hudson, Thomas J., Moreno, Victor, Sun, Wei, Huang, Wen-Yi, Lin, Yi, Cao, Yin, Peters, Ulrike, Hullar, Meredith, Phipps, Amanda I., Ugai, Tomotaka , Chen, Yu , Qu, Conghui , Chan, Andrew T , Um, Caroline Y. , Thomas, Claire E. , Buchanan, Daniel D. , Drew, David A. , Aglago, Elom K. , Brenner, Hermann , Figueiredo, Jane C. , Huyghe, Jeroen R. , Nowak, Jonathan A. , Doheny, Kimberly F. , Gunter, Marc J. , Giannakis, Marios , Jenkins, Mark A. , Obón‐Santacana, Mireia , Hoffmeister, Michael , Murphy, Neil , Georgeson, Peter , Campbell, Peter T., Trinh, Quang M. , Berndt, Sonja I. , Brezina, Stefanie , Gruber, Stephen B. , Gallinger, Steven , Zaidi, Syed H., Harrison, Tabitha A. , Hudson, Thomas J , Moreno, Victor , Sun, Wei, Huang, Wen‐Yi , Wang, Xiaoliang , Lin, Yi, Peters, Ulrike , Hullar, Meredith A.J. , Phipps, Amanda I. , Ogino, Shuji

Mayo Clinic

International Journal of Surgery | May 6, 2026 | Volume: 112 | Issue: 5 | Pages: 11070-11085

10.1097/js9.0000000000003877 Get It

Background: Considering the pathophysiological importance of the intestine-passing microbiota, we hypothesized that the mutational and microbial profiles of colorectal cancer might gradually change along detailed anatomical locations and that these trends might differ by the age of diagnosis and the microsatellite instability (MSI) status. Methods: We assessed somatic mutations and selected bacterial species in colorectal carcinomas along the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum, utilizing targeted sequencing data ( N = 5685) from the Genetics and Epidemiology of Colorectal Cancer Consortium and tissue microbial data ( N = 1389) from the Health Professionals Follow-up Study and Nurses’ Health Study. Results: There were decreasing trends from the cecum to rectum in the prevalence of gene mutations in the IGF/PI3K, receptor tyrosine kinase (RTK)/RAS, TGFB, and WNT signaling pathways (all P trend < 0.0001), as well as high levels of Bacteroides fragilis ( P trend < 0.0001) and high levels of Fusobacterium nucleatum ( P trend = 0.0029) (but not enterotoxigenic Bacteroides fragilis or pks+ Escherichia coli ). Conversely, TP53 pathway mutations showed an increasing cecum-to-rectum trend ( P trend < 0.0001). Similar to later-onset cases diagnosed at ages 50 years and older, in early-onset cases diagnosed under the age of 50 years, we found generally decreasing cecum-to-rectum trends of IGF/PI3K, RTK/RAS, TGFB, and WNT pathway mutations and an increasing cecum-to-rectum trend in TP53 pathway mutations. By contrast, the cecum-to-rectum prevalence-changing trends in IGF/PI3K, RTK/RAS, TGFB, and TP53 pathway mutations were present in non–MSI-high tumors but not in MSI-high tumors (all P interaction < 0.0052). Conclusion: Non–MSI-high colorectal cancers exhibited decreasing cecum-to-rectum trends of IGF/PI3K, RTK/RAS, and TGFB pathway mutations (and an increasing trend of TP53 pathway mutations), in contrast to MSI-high tumors that demonstrated no such trends. Our study highlights the importance of detailed colorectal subsite information combined with tumor molecular and microbial characteristics in colorectal cancer research.
ceQTL: a co-expression QTL model to detect a variant that affects transcription factor binding and its target regulation
Wang, Panwen , Chen, Yanxi, Liu, Yong, Yang, Ping , Wang, Junwen , Sun, Zhifu, Liu, Li , Yang, Ping , Wang, Junwen , Chen, Yanxi, Liu, Yong, Liu, Li

Mayo Clinic

Briefings in Bioinformatics | May 5, 2026 | Volume: 27 | Issue: 3 | Pages: No page available

10.1093/bib/bbag258 | PMID 42202282 Get It

Abstract Expression quantitative trait locus (eQTL) mapping is used to identify the functional link between a genomic variant and a gene’s expression. A significant eQTL association does not mean a causal relationship or mechanism, and further investigation is needed to understand how a single-nucleotide polymorphism (SNP) impacts gene expression. One of the most plausible explanations for eQTL is that a genomic variant affects transcription factor (TF) binding and thus impacts its regulation on target genes (TGs). However, the current eQTL model does not provide information on the TF and how its regulation is mediated by the SNP’s genotypes. Here, we propose a new method called differential co-expression QTL (ceQTL) among different alleles using Chow statistics to specifically detect eQTLs that are bound by a particular TF. We start with building a trio of TF, its TG, and related SNP, and then test the significant coefficient difference among different genotypes of the SNP. We applied this ceQTL model to simulated data and the lung tissue datasets from the genotype-tissue expression project. The simulated data results showed that the model was robust to detect true ceQTLs at variable sample sizes and different minor allele frequencies as measured by area under the curve. Our tool also performed a TF binding affinity analysis to add another layer of evidence for functional interpretation. In summary, ceQTL analysis provides a more interpretable and biological insight into the mechanism of eQTL and transcriptomic regulation, which would help us better understand how genomic variants affect phenotypes and diseases.
Association between bisphenols A and the risk of endometriosis: results from an updated meta-analysis
Chen, Yue, Wu, Junle, Wang, Yuxin , Yang, Qingxin, Zhu, Yan, Zhou, Qin, Li, Panpan, Wang, Fuke, Sun, Chenyu

Mayo Clinic

Frontiers in Public Health | May 4, 2026 | Volume: 14 | Issue: No issue available | Pages: No page available

10.3389/fpubh.2026.1817156 | PMID 42158187 Get It

Background Recent studies have disputed the association between bisphenol A (BPA) and endometriosis. This updated meta-analysis was conducted to investigate the impact of BPA exposure on endometriosis. Methods This study evaluated BPA exposure and endometriosis risk, analyzing studies from Web of Science, PubMed, Embase, Cochrane Library, and Chinese databases (CNKI, CBM, Wanfang, VIP) through August 2025. Methodological quality was assessed via the Newcastle-Ottawa Scale (NOS) and the Agency for Healthcare Research and Quality Tool (AHRQ). Heterogeneity was quantified using I 2 statistics. Pooled odds ratios (ORs) and 95% CIs were calculated using fixed- or random-effects models according to heterogeneity. Subgroup analysis, sensitivity analysis, and publication bias assessment were supplemented to validate the overall finding. Results Seven studies comprising 2,488 participants were included in quantitative synthesis. The meta-analyses demonstrated that BPA exposure was associated with a statistically significant increase in endometriosis risk (OR = 1.36, 95% CI = 1.13–1.63, p = 0.008). Additionally, subgroup analysis indicated that BPA exposure may further elevate endometriosis risk in cases with different regions, populations, and measurement methods. Sensitivity analysis confirmed that the results of these meta-analyses were relatively robust. No publication bias was detected. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251019552 , identifier PROSPERO (CRD420251019552).